Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its full year 2020 financial results on Thursday, February 25th, 2021.
GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc., (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its full year 2020 financial results on Thursday, February 25th, 2021.
Altimmune management will host a conference call for investors beginning at 8:30 am ET on Thursday, February 25th, 2021 to discuss financial results and provide a business update.
Conference Call Information:
| Date: | Thursday, February 25, 2021 |
| Time: | 8:30 am Eastern Time |
| Domestic Dial-in: | 877-423-9813 |
| International Dial-in: | 201-689-8573 |
| Conference ID: | 13716171 |
| Webcast: | http://public.viavid.com/index.php?id=143423 |
About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.
Investor & Media Contacts:
| Will Brown | Stacey Jurchison |
| Chief Financial Officer | Sr. Dir, Investor Relations |
| Phone: 240-654-1450 | Phone : 410-474-8200 |
| wbrown@altimmune.com | sjurchison@altimmune.com |
